2019
Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy
Massicano AVF, Lee S, Crenshaw BK, Aweda TA, Sayed R, Super I, Bose R, Marquez-Nostra BV, Lapi SE. Imaging of HER2 with [89Zr]pertuzumab in Response to T-DM1 Therapy. Cancer Biotherapy & Radiopharmaceuticals 2019, 34: 209-217. PMID: 30676778, PMCID: PMC7227434, DOI: 10.1089/cbr.2018.2654.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAnimalsAntibodies, Monoclonal, HumanizedBreast NeoplasmsCell Line, TumorDeferoxamineFemaleHumansIsothiocyanatesMaytansineMiceMice, NudePositron Emission Tomography Computed TomographyRadioisotopesRadiopharmaceuticalsReceptor, ErbB-2TrastuzumabTreatment OutcomeTumor BurdenXenograft Model Antitumor AssaysX-Ray MicrotomographyZirconiumConceptsT-DM1 therapyBreast cancerTumor volumeHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2BT-474 tumorsGrowth factor receptor 2HER2-positive tumorsFactor receptor 2HER2 expressionBCa patientsReceptor 2TherapyTumorsEarly responseBetter delineationPertuzumabPoor delineationMBq/MiceTreatmentResponsePatientsHER2
2018
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts. Journal Of Nuclear Medicine 2018, 59: 1219-1224. PMID: 29348316, PMCID: PMC6071500, DOI: 10.2967/jnumed.117.203299.Peer-Reviewed Original ResearchConceptsTumor uptakeCD20 antibodyLymphoma xenograftsMonoclonal antibodiesDrug AdministrationBurkitt's lymphoma xenograftsHigher splenic uptakeAnti-CD20 antibodyCD20 monoclonal antibodyPET/CT imagingHuman lymphoma xenograftsSmall-animal PET/CT imagesPreclinical mouse modelsB-cell lymphomaPET/CTPET/CT imagesHigh tumor uptakeNext-Generation AntiClear tumor uptakePalpable tumorsSplenic uptakeImmunodeficient miceEffective treatmentMouse modelObinutuzumab